Insmed Inc (INSM)vsPrelude Therapeutics Inc (PRLD)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
PRLD
Prelude Therapeutics Inc
$3.26
+4.49%
HEALTHCARE · Cap: $198.65M
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 4895% more annual revenue ($606.42M vs $12.14M). PRLD leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
PRLD
Avoid32
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Revenue surging 41.0% year-over-year
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -99.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : PRLD
The strongest argument for PRLD centers on Revenue Growth. Revenue growth of 41.0% demonstrates continued momentum.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : PRLD
The primary concerns for PRLD are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while PRLD is a hypergrowth play — different risk/reward profiles.
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
PRLD is growing revenue faster at 41.0% — sustainability is the question.
PRLD generates stronger free cash flow (23M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 32/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Prelude Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Prelude Therapeutics Incorporated, a precision clinical-stage oncology company, focuses on the discovery and development of small molecule therapies optimized to target key drivers in cancers. The company is headquartered in Wilmington, Delaware.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?